Login
Communauté Vinci
Extérieur
Si votre nom d'utilisateur ne se termine pas par @vinci.be ou @student.vinci.be, utilisez le formulaire ci-dessous pour accéder à votre compte de lecteur.
Titre : | Therapeutical use of probiotic formulations in clinical practice (2011) |
Auteurs : | T. Iannitti, Auteur ; B. Palmieri, Auteur |
Type de document : | Article |
Dans : | Clinical nutrition (vol 29, n° 6, 2011) |
Article en page(s) : | 701-725 |
Langues: | Français |
Descripteurs : |
HE Vinci Microbiome gastro-intestinal ; Probiotiques ; Thérapeutique |
Résumé : |
Background & Aims
The spreading of gastrointestinal diseases is growing all over the world. Although for some of them an effective therapeutic approach has been found, palliation rather than cure is very frequent due to a partial knowledge of their aethiology and pathogenesis. This review, analyzing the main clinical studies, aims at being a state of the art update of the use of probiotic formulations in daily practice. Methods In this review we include all the most significant clinical trials involving the use of probiotic formulations for the treatment of several pathologies. Results Dysbiosis has been observed in irritable bowel syndrome patients. Probiotics may exert a beneficial effect on Crohns disease affected patients who have shown gut microbiota antigens and altered wall permeability. Moreover some probiotic formulations seem to enhance the therapy for Helycobacter Pylori reducing its pathogenic potential. Intestinal ecology imbalance has been also linked to cancer induction, allergy, skin and urogenital diseases. In addition probiotics administration seems to be particularly useful to ease post-operative complications. Conclusion Further future clinical trials, involving large numbers of patients, will be mandatory to achieve definite evidence of the preventive and curative role of probiotics in medical practice. Keywords: Probiotic; Microbiota; Dysbiosis; Disease Article Outline 1. Introduction 1.1. Normal bacterial flora of the GI tract 1.2. Dysbiosis 1.3. Probiotics, prebiotics and synbiotics 2. Short chain fructooligosaccharides(sc-FOS) 2.1. The safety of probiotics: goods and flaws 2.2. Probiotics and immunity 2.3. Probiotics, skin disease and allergy 2.4. Probiotics in surgical practice 2.5. Urogenital infections 2.6. Probiotics and renal diseases 3. Probiotics and GI diseases 3.1. Diverticular disease 3.2. Irritable bowel syndrome 3.3. Inflammatory bowel disease clinical trials 3.4. Helicobacter pylori eradication 3.5. Cancerogenesis 3.6. Diarrhea 3.7. Mixed studies on Probiotics 4. Conclusion |
Disponible en ligne : | Non |
Exemplaires (1)
Cote | Support | Localisation | Section | Disponibilité |
---|---|---|---|---|
REV | Périodique papier | Woluwe | Espace revues | Prêt autorisé Disponible |